Skip to main content
. 2021 Jan 16;12(6):1660–1668. doi: 10.7150/jca.47344

Figure 3.

Figure 3

Knockdown of SNHG25 inhibits ovarian cancer cell proliferation in vitro and in vivo. A(i-ii)-B(i-iii): CCK-8 cell viability assay and colony formation assay showing decreased proliferation in SNHG25 knockdown compared to control A2780 and OVCAR3 cells (n(LV-NC)=3, n(LV-KD)=3); C(i-iii): Flow cytometry showing increased apoptosis in SNHG25 knockdown compared to control A2780 and OVCAR3 cells (n(LV-NC)=3, n(LV-KD)=3); D(i-ii): Downregulation of SNHG25 inhibited the growth (tumor volume) of subcutaneous xenografts in nude mice (n(LV-NC)=6, n(LV-KD)=6). (*P<0.05, **P<0.01, ***P<0.001, ****P <0.0001).